Avenue Therapeutics IncNASDAQ:ATXINASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE6.2000
- TODAY'S CHANGE (%)-2.5750 (-29.3447%)
- Bid / Lots6.2600/ 1
- Ask / Lots6.7500/ 1
- Open / Previous Close7.4800 / 8.7750
- Day Range
- 52 Week Range
- Volume235,516
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ATXI |
|---|---|---|
| 09:32 ET | 1407 | 7.58 |
| 09:34 ET | 994 | 7.42 |
| 09:36 ET | 1689 | 7.4 |
| 09:38 ET | 613 | 7.29 |
| 09:39 ET | 5554 | 7.4897 |
| 09:41 ET | 2367 | 8.14 |
| 09:52 ET | 6407 | 8.22 |
| 09:54 ET | 2101 | 7.9106 |
| 09:56 ET | 5609 | 8.5 |
| 09:57 ET | 17588 | 8.75 |
| 09:59 ET | 1950 | 8.73 |
| 10:01 ET | 6469 | 8.2 |
| 10:03 ET | 673 | 8.16 |
| 10:06 ET | 1375 | 8.01 |
| 10:08 ET | 200 | 8.15 |
| 10:10 ET | 4363 | 7.86 |
| 10:12 ET | 700 | 8 |
| 10:15 ET | 203 | 7.85 |
| 10:17 ET | 787 | 7.85 |
| 10:19 ET | 135 | 7.61 |
| 10:21 ET | 4393 | 7.99 |
| 10:28 ET | 130 | 7.8534 |
| 10:30 ET | 300 | 7.7001 |
| 10:33 ET | 243 | 7.6424 |
| 10:35 ET | 2639 | 7.4028 |
| 10:37 ET | 399 | 7.31 |
| 10:39 ET | 497 | 7.26 |
| 10:42 ET | 200 | 7.4 |
| 10:53 ET | 1000 | 7.5001 |
| 10:55 ET | 286 | 7.595 |
| 11:02 ET | 100 | 7.59 |
| 11:06 ET | 675 | 7.75 |
| 11:08 ET | 740 | 7.47 |
| 11:11 ET | 267 | 7.4101 |
| 11:15 ET | 100 | 7.525 |
| 11:18 ET | 2082 | 7.4188 |
| 11:27 ET | 133 | 7.4277 |
| 11:29 ET | 261 | 7.42 |
| 11:33 ET | 121 | 7.41 |
| 11:40 ET | 588 | 7.41 |
| 11:45 ET | 400 | 7.41 |
| 11:47 ET | 206 | 7.4201 |
| 11:51 ET | 100 | 7.45 |
| 11:54 ET | 2020 | 7.65 |
| 12:03 ET | 200 | 7.65 |
| 12:07 ET | 959 | 7.62 |
| 12:12 ET | 409 | 7.66 |
| 12:25 ET | 201 | 7.5 |
| 12:41 ET | 250 | 7.66 |
| 12:43 ET | 100 | 7.5 |
| 12:45 ET | 130 | 7.5147 |
| 12:48 ET | 100 | 7.52 |
| 12:52 ET | 1302 | 7.5283 |
| 01:01 ET | 302 | 7.48 |
| 01:03 ET | 461 | 7.48 |
| 01:06 ET | 337 | 7.3853 |
| 01:08 ET | 1427 | 7.22 |
| 01:10 ET | 633 | 7.12 |
| 01:12 ET | 400 | 7.2 |
| 01:17 ET | 2480 | 7.1999 |
| 01:21 ET | 1050 | 7.29 |
| 01:24 ET | 400 | 7.2741 |
| 01:26 ET | 2000 | 7.2527 |
| 01:30 ET | 570 | 7.34 |
| 01:32 ET | 1362 | 7.34 |
| 01:42 ET | 332 | 7.33 |
| 01:48 ET | 260 | 7.4 |
| 01:50 ET | 300 | 7.41 |
| 02:31 ET | 1106 | 7.36 |
| 02:33 ET | 600 | 7.36 |
| 02:36 ET | 100 | 7.36 |
| 02:38 ET | 200 | 7.36 |
| 02:42 ET | 100 | 7.31 |
| 02:47 ET | 300 | 7.32 |
| 02:49 ET | 301 | 7.27 |
| 02:56 ET | 100 | 7.26 |
| 02:58 ET | 100 | 7.305 |
| 03:00 ET | 500 | 7.32 |
| 03:02 ET | 1251 | 7.33 |
| 03:18 ET | 204 | 7.319 |
| 03:27 ET | 14722 | 7.1403 |
| 03:30 ET | 3005 | 6.93 |
| 03:32 ET | 1825 | 6.8 |
| 03:34 ET | 282 | 6.81 |
| 03:39 ET | 571 | 6.66 |
| 03:41 ET | 515 | 6.7164 |
| 03:43 ET | 300 | 6.8 |
| 03:45 ET | 1481 | 6.9539 |
| 03:48 ET | 244 | 6.92 |
| 03:54 ET | 15104 | 6.11 |
| 03:56 ET | 20373 | 5.9656 |
| 03:57 ET | 300 | 6.15 |
| 03:59 ET | 3557 | 6.2 |
Apr 24, 2024
*DJ Avenue Therapeutics Will Effect a 1-For-75 Reverse Split >ATXI, from 7:31AM ET on Wednesday Apr 24, 2024 by Dow Jones
7:31AM ET on Wednesday Apr 24, 2024 by Dow JonesAvenue Therapeutics Announces Reverse Stock Split, from 7:30AM ET on Wednesday Apr 24, 2024 by Dow Jones
7:30AM ET on Wednesday Apr 24, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Avenue Therapeutics Inc | 274.4M | 0.0x | --- |
Inozyme Pharma Inc | 274.3M | -3.2x | --- |
Ventyx Biosciences Inc | 276.8M | -1.2x | --- |
Opthea Ltd | 270.0M | -1.4x | --- |
ESSA Pharma Inc | 269.0M | -10.4x | --- |
Zura Bio Ltd | 280.8M | -1.0x | --- |
Company Information
Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. The Company is developing three assets including AJ201, an asset for spinal and bulbar muscular atrophy; BAER-101, an oral small molecule selective Gamma-aminobutyric acid receptor A alpha 2 & 3 (GABAA α2, α3) receptor positive allosteric modulator for central nervous system (CNS) diseases; and IV tramadol, which is in phase III clinical development for the management of acute postoperative pain in adults in a medically supervised healthcare setting. AJ201 is a pleiotropic small molecule that is designed to modify multiple mechanisms including degradation of the abnormal AR protein and stimulation of Nrf1 and Nrf2, which are involved in protecting cells form oxidative stress which can lead to cell death. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties.
Contact Information
- Headquarters
- 1111 KANE CONCOURSE, SUITE 301BAY HARBOR ISLANDS, FL, United States 33154
- Phone
- 781-652-4500
- Fax
- 302-531-3150
Executives
- Non-Executive Chairman of the Board
- Jay Kranzler
- Chief Executive Officer, Director
- Alexandra Maclean
- Interim Chief Financial Officer, Chief Operating Officer
- David Jin
- Director
- Lindsay Rosenwald
- Independent Director
- Faith Charles
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $274.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 44.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.16 |
EPS | $-133.23 |
Book Value | $4.64 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
